After the listing: from final prospectus to first 10-Q

For the teacher. Every number comes from the filing named next to it.

Part A

Accept results (revenue, profit or loss), what changed from a year earlier, risks, and what the company did with its money.

Part B

1. Pricing (the 424B4 is dated). 2. Trading begins. 3. The 424B4 is filed, within two business days. 4. First earnings release (8-K). 5. First 10-Q. B1. For each of the first three quarters of its fiscal year (the fourth is in the 10-K).

Part C

C1. 424B4 dated Mar 27, 2025 (filed Mar 31, 2025); trading began Mar 28, 2025; first 10-Q filed May 15, 2025.

Where: CoreWeave Form 424B4; Form 10-Q for Q1 FY2025

C2. ($982 million − $188.7 million) ÷ $188.7 million × 100 = 420.4% (Cityfort calculation).

Where: CoreWeave Form 10-Q for Q1 FY2025, statements of operations

C3. Bigger: $314.6 million against $129.2 million.

C4. Smaller: $290 million against $323 million.

Where: CoreWeave Form 10-Q for Q2 FY2025, statements of operations

Part D

D1. The quarter ended Sep 30, 2026, the first quarter after the Jun 30, 2026 statements in its prospectus.

D2. The quarter ended Sep 30, 2026, the first quarter after the Jun 30, 2026 statements in their prospectuses.

D3. Part II, in the item on unregistered sales of equity securities and use of proceeds.

Not accepted on any part: "a winner," "a flop," "popped" or any statement about the share price.

Advanced

Accept any accurate quotation from that item with its page; check it against the filing.

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Exit ticket

1. The final prospectus, filed after the shares are priced.

2. Many businesses have seasons, so the same quarter a year earlier is the closest match.

3. ($65 million − $50 million) ÷ $50 million × 100 = 30%.

4. Part II, the item on use of proceeds.

Notes

- Data checked Nov 15, 2026. CoreWeave's figures are copied from its Cityfort stock page, which takes them from its 10-Qs and earnings releases. Listing dates come from each company's stock page and final prospectus. The lesson shows no prices or price changes.

Sources

1. S1: CoreWeave: Form 424B4 final prospectus, IPO (dated Mar 27, 2025), CoreWeave, Inc. (SEC EDGAR), Mar 31, 2025. https://www.sec.gov/Archives/edgar/data/1769628/000119312525067651/d899798d424b4.htm
2. S2: CoreWeave: Q1 FY2025 earnings release (Form 8-K, Exhibit 99.1), CoreWeave, Inc. (SEC EDGAR), May 14, 2025. https://www.sec.gov/Archives/edgar/data/1769628/000176962825000010/coreweave1q25earningspress.htm
3. S3: CoreWeave: Form 10-Q, Q1 FY2025 (quarter ended Mar 31, 2025), CoreWeave, Inc. (SEC EDGAR), May 15, 2025. https://www.sec.gov/Archives/edgar/data/1769628/000176962825000014/crwv-20250331.htm
4. S4: CoreWeave: Form 10-Q, Q2 FY2025 (quarter ended Jun 30, 2025), CoreWeave, Inc. (SEC EDGAR), Aug 13, 2025. https://www.sec.gov/Archives/edgar/data/1769628/000176962825000041/crwv-20250630.htm
5. S5: Accelevation Holdings Corp. Form 424(b)(4) final prospectus dated Sep 29, 2026, filed Oct 1, 2026, Accelevation Holdings Corp. (SEC EDGAR), Oct 1, 2026. https://www.sec.gov/Archives/edgar/data/2141406/000162828026064097/accelevationllc-424b4.htm
6. S6: City Therapeutics, Inc. final prospectus (Form 424B4), dated Oct 15, 2026, City Therapeutics, Inc. (SEC EDGAR), Oct 16, 2026. https://www.sec.gov/Archives/edgar/data/2143850/000110465926116636/tm2619715-10_424b4.htm
7. S7: Lycia Therapeutics: Form 424B4 final prospectus, initial public offering (dated Oct 22, 2026), Lycia Therapeutics, Inc. (SEC EDGAR), Oct 23, 2026. https://www.sec.gov/Archives/edgar/data/1806540/000162828026067048/lyciatherapeutics-424b4.htm

Credit and license

"Where does IPO money go?: Lesson 4 – After the listing: from final prospectus to first 10-Q" by Cityfort (cityfort.co/teachers/where-does-ipo-money-go/after-the-listing), CC BY-NC 4.0. Data from CoreWeave's IPO Form 424B4 final prospectus, filed Mar 31, 2025; CoreWeave's Q1 FY2025 earnings release (Form 8-K), filed May 14, 2025; CoreWeave's Q1 FY2025 Form 10-Q, filed May 15, 2025; CoreWeave's Q2 FY2025 Form 10-Q, filed Aug 13, 2025; Accelevation's IPO Form 424B4 final prospectus, filed Oct 1, 2026; City Therapeutics's IPO Form 424B4 final prospectus, filed Oct 16, 2026; and Lycia Therapeutics's IPO Form 424B4 final prospectus, filed Oct 23, 2026.

If you change this material, please remove the Cityfort name or mark it as modified; changed versions are not reviewed by Cityfort. Company names are trademarks of their owners; Cityfort is not affiliated with or endorsed by them.

No ads in any lesson file. Student pages carry at most one non-personalized ad. No student logins. Questions or corrections: cityfort.co/contact.

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Data from CoreWeave's IPO Form 424B4 final prospectus, filed Mar 31, 2025; CoreWeave's Q1 FY2025 earnings release (Form 8-K), filed May 14, 2025; CoreWeave's Q1 FY2025 Form 10-Q, filed May 15, 2025; CoreWeave's Q2 FY2025 Form 10-Q, filed Aug 13, 2025; Accelevation's IPO Form 424B4 final prospectus, filed Oct 1, 2026; City Therapeutics's IPO Form 424B4 final prospectus, filed Oct 16, 2026; and Lycia Therapeutics's IPO Form 424B4 final prospectus, filed Oct 23, 2026. Checked Nov 15, 2026.

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.